Medimetriks Pharmaceuticals, Inc. Begins Operations
May 13 2008 - 7:18AM
PR Newswire (US)
Bradley Pharmaceuticals Founder and Senior Management Form Company
Specializing in Dermatology and Podiatry Markets FAIRFIELD, N.J.,
May 13 /PRNewswire/ -- Medimetriks Pharmaceuticals, Inc. announced
today that it commenced operations. The newly-formed Company, led
by the founder and the key Senior Management Team of the former
Bradley Pharmaceuticals (NYSE:BDY), will develop, license and
commercialize innovative prescription products for the Dermatology
and Podiatry marketplaces. The Company is aggressively pursuing
licensing opportunities, company and product acquisitions and
initiating the development of a series of brands that will fill
unmet needs in the marketplace. Medimetriks' objective is to build
a robust product portfolio and become a leading Dermatology and
Podiatry specialty company. Bradley Pharmaceuticals was acquired
earlier this year by Nycomed for approximately $350MM. Bradley's
Doak Dermatologics Division, which represented approximately 80% of
Bradley's revenue, was a leading dermatology company and the
largest independent pharmaceutical marketer to the podiatry
specialty. Bradley Glassman, the former Senior Vice President of
Sales and Marketing for Bradley, will serve as President and CEO of
Medimetriks Pharmaceuticals, Brent Lenczycki as Chief Financial
Officer and Alan Goldstein as Executive Vice President, Business
Development. Daniel Glassman, the former President and CEO of
Bradley, will serve as Medimetriks' Chairman of the Board. "We have
an experienced management team that was an important part of
Bradley's success," stated Daniel Glassman. "We also have added a
strong support team that will allow Medimetriks to achieve both
short and long term success. Medimetriks' talented staff
demonstrates a tremendous ability to execute with discipline and
shares a commitment to creating a meaningful Company that will
enhance patient care." Bradley Glassman said, "We will leverage our
core expertise of identifying and delivering important and
effective brands in the therapeutic markets that we know so well.
In building the Bradley business, we developed long-standing
relationships with leading physicians in both the Dermatology and
Podiatry specialties. We look forward to working with these
physicians and building brands that serve the interests of both
their practices and their patients." The Company is located at 363
Route 46 West, Suite 106, Fairfield, NJ 07004-2402. Please visit
the Medimetriks website at http://www.medimetriks.com/ .
DATASOURCE: Medimetriks Pharmaceuticals, Inc. CONTACT: David Addis,
Senior VP, Brand Communication of Medimetriks Pharmaceuticals,
Inc., Web site: http://www.medimetriks.com/
Copyright
Bradley (NYSE:BDY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bradley (NYSE:BDY)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Bradley Pharmaceuticals (New York Stock Exchange): 0 recent articles
More Bradley Pharmaceuticals News Articles